Why Crinetics Stock Soared 99% This Week

By Danielle Liverance Published Jul 9, 1:29PM EDT

Quick Read

Vertex's $85-per-share all-cash acquisition sent CRNX up 116% on a franchise the company projects will exceed $5B in peak annual sales.
NBIX gained 6% and CORT rose 5% as investors repriced endocrine rare-disease specialists as potential M&A targets following the deal.
Trading just under the $85 cash offer, CRNX upside is capped unless a competing bid emerges before the expected Q3 2026 close.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Crinetics Pharmaceuticals didn't make the cut. Grab the names FREE today.

Why Crinetics Stock Soared 99% This Week — © 24/7 Wall St.

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it.

Vertex’s $10 Billion All-Cash Bid Fuels the Surge

The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 billion, or $85.00 per share in all cash. The transaction was unanimously approved by both boards and is expected to close in Q3 2026. Vertex plans to finance the deal with cash and debt.

The prize is Crinetics’ endocrine franchise. PALSONIFY (paltusotine), the first once-daily oral somatostatin receptor type 2 nonpeptide agonist for acromegaly, cleared the FDA in September 2025 and won European Commission approval in April 2026. Q1 2026 product sales hit $10.31 million, with 263 unique prescribers and roughly 70% of patients on reimbursed therapy. Behind PALSONIFY sits atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Vertex projects the acquired assets could deliver over $5 billion in peak annual sales and contribute earnings accretion by 2029.

Endocrine Peers Get a Re-Rating Look

Vertex is stepping outside cystic fibrosis and building a fifth business group in endocrine diseases, and that validation puts a fresh spotlight on the small cluster of rare-disease specialists in the same neighborhood. Vertex shares themselves barely moved on the week, gaining 0.08% to $498.43, reflecting investor caution about the price tag.

The most direct competitive read-throughs are into Cushing’s syndrome and CAH. Neurocrine Biosciences (NASDAQ:NBIX) markets CRENESSITY (crinecerfont) for classic CAH, which posted $153.30 million in Q1 2026 revenue and overlaps directly with Crinetics’ atumelnant program. Neurocrine stock added 6.24% over the past week. Corcept Therapeutics (NASDAQ:CORT), whose relacorilant is in development for Cushing’s syndrome alongside its newly approved ovarian cancer indication Lifyorli, rose 5.04%. Ascendis Pharma (NASDAQ:ASND), an adjacent endocrine rare-disease peer with YORVIPATH and YUVIWEL, gained 3.51%.

Those moves arrive against a backdrop where a scaled acquirer just paid roughly $85 per share for a company whose analyst target sat at $83.73 and whose full-year 2026 revenue is pegged around $69 million. Investors sifting for the next endocrine tuck-in are exactly the audience that reads through to names like these, which is one reason breakout-driven M&A watchlists get updated after weeks like this one.

What to Watch

With CRNX at $83.54 and Vertex’s cash offer fixed at $85.00, the arbitrage spread is narrow and the ceiling is defined. Absent a competing bid, upside from here is capped. Investors should track the expected Q3 2026 close plus any HSR or regulatory commentary – all of which will help us understand where things go from here.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google

About the Author Danielle Liverance →

I've spent more than 15 years inside enterprise software, working alongside the finance, sales operations, and HR leaders who run the revenue engines at some of the largest tech companies in the country.

My day job is helping enterprise executives make smarter decisions about retention, compensation, and growth. These are the same operational levers that show up in every earnings report investors actually read. That perspective shapes my writing for 24/7 Wall St.

The headline numbers are easy. The interesting stuff is underneath: how companies make money, what executives are worried about, and what any of it means for the person checking their 401(k) on a Sunday afternoon. I write about personal finance and business as someone who has spent her career inside the rooms where these decisions get made.